The family that owns Spanish drugmaker Grifols and private equity firm Brookfield are considering whether to take the company private in a deal that could be worth around €5.5 billion (almost $6 ...

to back the take-private of Spanish pharmaceutical producer Grifols SA. Lenders are preparing to send final proposals next week, with the expectation that a bank group will be appointed by the end ...

(Bloomberg) -- Just when it looked like the worst was over for the Spanish family behind one of the world’s biggest medical fortunes, its financial woes plumbed to a new low. The Grifols family ...

its chairman said in a newspaper interview published on Sunday. Spanish drug maker Grifols will bring in independent directors, chairman tells newspaper Reuters, the news and media division of ...

Mason Capital Management, a registered investment advisor to funds and accounts holding approximately 2.1% of Grifols (GRFS) class A shares, ...

Brookfield Asset Management is awaiting information from Grifols SA about related-party transactions as it seeks to complete its due diligence on the business, according to a person familiar with ...

Brookfield still hasn't managed to obtain the €9.5 billion of bank financing to repay Grifols’ debt, nor the €3.5 billion it ...

Spanish drugmaker Grifols has hit back at hedge fund Gotham City Research, which claimed it had fraudulently manipulated its financial reporting, with a lawsuit filed in New York. The complaint ...